Flavoxate ( DrugBank: Flavoxate )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 226 | 間質性膀胱炎（ハンナ型） | 1 |
226. 間質性膀胱炎（ハンナ型）
臨床試験数 : 145 / 薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs051210106 | 13/10/2021 | 13/10/2021 | ESTOC study | The Effect of Suplatast Tosilate for interstitial Cystitis: A randomized controlled open-label trial - ESTOC study | Interstitial cystitis bladder, inflammation, pain;D018856 | Participants will be randomly assigned to splatast group or control group. In splatast group, splatast tosilate capsule 100 mg (1 capsule at a time) will be orally administered 3 times a day between meals for 3 months. In control group, flavoxate hydrochloride tablets 200 mg (1 tablet at a time) will be orally administered 3 times a day between meals for 3 months. | Torimoto Kazumasa | Fujimoto Kiyohide | Recruiting | >= 20age old | Not applicable | Both | 100 | Phase 2 | Japan |